publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
viral
infect
solid
transplant
patient
p
dhpg
combin
u
ifn
f
inhibit
l
l
p
dhpg
combin
ngd
ifn
n
conclus
ifn
ifn
decreas
hcmv
infect
monocyticlik
cell
line
may
lead
improv
avail
chemotherapi
import
human
pathogen
combin
ifn
dhpg
lnfection
show
synergist
effect
pcv
welldocu
inhibitori
activ
herp
simplex
viru
variceliazost
viru
contrast
data
activ
cmv
limit
evalu
vim
activ
pcv
cmv
ws
marmw
transplant
recipi
neonat
cmv
strain
compar
result
obtain
parallel
acyclovir
acv
ganciclovir
gcv
foscarnet
fo
plaqu
reduct
assay
use
determin
mhibitori
drug
concentr
reduc
plaqu
number
drug
test
human
fibroblast
cell
line
result
follow
median
icsg
p
indxatmg
rerkunc
ganclclovlr
pool
icso
pcv
cmv
strain
significantli
higher
acv
gcv
fo
p
comparison
howev
valu
obtain
must
also
consid
context
pharmacokinet
toxicolog
properti
drug
test
activ
pcv
cmv
investig
vivo
twelv
patient
differ
form
haematolog
malign
underw
autolog
n
allogen
n
bmt
test
materi
blood
sera
nasal
swab
collect
week
month
preand
posttransplant
period
nasal
swab
wash
l
ml
pb
materi
subject
sediment
sediment
nasal
epithelium
cell
use
direct
immunofluoresc
microscopi
perform
fluoresceinconjug
antibodi
ab
respiratori
virus
mycoplatma
pneumonia
mp
supernat
use
detect
mucos
ab
detect
ab
well
ab
blood
sera
perform
indirect
haemagglutin
test
iha
viral
injuenra
fype
adenovinr
rezpirntori
viru
coronavincc
mp
antigen
bacteri
fungal
infect
diagnos
microbiolog
episod
infect
diagnos
episod
mix
mpviral
infect
demonstr
twenti
five
episod
detect
immunosuppress
patient
period
profound
neutropenia
immedi
bmt
clinic
manifest
invas
bacteri
infect
caus
eschmchia
coli
mebsiella
pneumonia
pseudomom
amginosa
sever
episod
preexist
respiratori
viralmp
infect
viralmycoplasm
respiratori
infect
decreas
resist
bacteria
immunosuppress
patient
immun
respons
patient
character
dramat
decreas
blood
ab
level
wherea
mucos
ab
chang
similarli
immunocompet
patient
conclud
viralmycoplasm
infect
enhanc
immunodepress
immunosuppress
patient
especi
gener
immun
respons
rather
local
one
infect
must
caremi
control
u
jacob
nies
hu
klehr
medic
dept
univenifi
hosp
bonn
germ
object
enhanc
allogen
cmv
may
induc
acut
reject
well
chronic
transplant
tp
damag
via
endotheli
mitogen
lesion
method
subset
renal
allograft
patient
p
analys
cmv
incid
onset
risk
profil
evalu
earli
sensit
cytoimmunolog
lymphocyt
subset
fac
viral
diagnost
workup
weekli
tx
antigen
ea
pcr
cmvigmtit
eljsa
techn
viru
isol
urin
throat
swab
well
impact
earli
virustat
intervent
acut
longterm
tp
function
sumval
cmv
diseas
defin
combin
one
viral
paramet
plu
organ
deterior
result
incid
cmv
diseas
posttranspl
associ
monoclon
antibodi
therapi
acut
reject
independ
recipi
statu
pretranspl
posit
donor
cmvigg
increas
risk
diseas
addit
earli
diagnost
sensit
invers
earli
antigen
igm
seroconvers
viru
isol
p
recurr
cmv
diseas
pcr
marker
lnfection
regardless
diseas
leucocyt
decreas
f
f
clinal
predict
valu
characterist
nocturn
hyperhidrosi
p
cmv
diseas
complain
accompani
inversiondecreas
increas
result
ratio
preced
acut
organ
deterior
degre
invers
reflect
sever
cmv
diseas
cours
diagnost
valu
paramet
impair
even
p
monoclon
antibodi
consequ
virustat
therapi
contribut
improv
transplant
function
decreas
serumcreatinin
om
f
f
mgdl
advers
effect
associ
ganciclovir
drug
resist
one
year
graft
sumval
improv
without
cmv
complic
statist
analysi
f
yr
followup
period
exclud
remain
impact
previou
cmv
diseas
longterm
tp
function
actuari
creatinin
proteinuria
object
renal
transplant
surviv
rate
could
improv
throughout
last
year
transplant
care
unit
due
efficaci
steroid
resist
acut
reject
episod
earli
intervent
cmv
infect
often
knked
strong
immunosuppress
regim
small
experi
reactiv
infect
transplant
esp
treatment
case
report
therefor
report
old
male
patient
sufter
sever
dection
fever
leucopenia
fatigu
transplant
dysfunct
week
allografang
overcom
reject
episod
treat
cortison
atg
twice
resp
primari
cmv
infect
transmit
posit
donor
transplant
manifest
hrst
cours
requir
ganciclovir
weekli
wal
workup
cmv
reactiv
could
exclud
evid
strong
viral
infect
conthous
decreas
invers
within
lymphocyt
subset
mean
standardu
weekli
viral
monitor
antibodi
detect
fluorescenceserolog
high
degre
first
time
date
p
known
posit
sirmkr
cmv
infect
strong
serolog
evid
widespread
lnfection
gener
popul
far
diseas
definit
h
k
e
exanthema
subitum
chlldhood
therapeut
effect
antivir
agent
test
vim
p
onset
consequ
virustat
treatment
gancidovir
allograft
function
could
improv
igmseroconvers
overcom
serumcreatinin
decreas
h
wmoll
leucocyt
recov
one
year
followup
stabl
renal
transplant
function
convent
thempi
cyclosporin
steroid
azathioprin
maintain
conclus
repeat
dosag
regim
may
trigger
sever
infect
reactiv
result
transplant
damag
daerenti
bgnosi
focu
rhu
viru
transplant
esp
exclus
cmv
ganciclovir
reveal
potent
antivir
agent
infect
vivo
method
dna
h
leukocyt
isol
glass
bead
semiquantit
nest
polymeras
chain
reaction
pcr
two
set
primer
e
region
use
sensit
pcr
copi
viral
genom
igm
determin
elisa
result
sampl
blood
saliva
urin
patient
transplant
month
investig
patient
acut
symptom
cmvdiseas
minor
unclear
c
h
c
l
symptom
patient
cmv
dna
blood
pcr
copi
leukocyt
h
cmv
dna
urin
also
saliva
fell
cmvdiseas
later
rise
cmv
dna
level
among
other
pcrneg
blood
patient
cmv
dna
urin
saliva
padent
effect
ganciclovir
therapi
other
cmv
dna
neither
urin
saliva
patient
low
dna
signal
blood
intens
dna
signal
recipi
urin
saliva
igm
posit
patient
anticmv
drug
therapi
earli
result
obtain
pcr
blood
patient
without
acut
onset
cmvdiseas
nt
coincid
urin
saliva
cmv
dna
present
werent
biolog
materi
urin
saliva
amount
viral
dna
essenti
blood
level
cmv
dna
without
symptom
cmvbase
patient
low
semiquantit
detect
cmv
dna
blood
success
eas
diagnosi
urin
saliva
method
dna
leukocyt
isol
glass
bead
semiquantit
nest
pcr
two
set
primer
e
region
use
sensit
pcr
copi
viral
dna
igg
igm
determin
elisa
result
patient
investig
patient
cmvposit
pcr
quantiti
cmv
dna
correl
clinic
manifest
patient
copi
viral
dna
leukocyt
acut
cmv
diseas
blood
sampl
h
patient
activ
cmvinfect
drawn
interv
day
transplant
patient
copi
subfebril
temperatur
andlor
gastrointestin
symptom
effect
ganciclovir
therapi
wal
dna
clean
rule
patient
without
clincal
symptom
cmv
dna
detect
month
igm
igg
antibodi
correl
cmv
diseas
badli
among
anticmv
igmposit
sampl
pcrposit
among
igmneg
sampl
pcrposit
igm
antibodi
cmv
dna
blood
patient
bmt
detect
month
finish
drug
therapi
without
rise
igg
antibodi
titr
without
clinic
symptom
igm
antibodi
also
appear
week
later
cmv
dna
onset
diseas
conclus
pcr
direct
sensit
method
diagnosi
activ
cmv
mfection
amount
cmv
dna
copi
leukocyt
correl
cmv
diseas
igm
igg
detect
low
agnost
valu
object
estim
incid
rate
hcv
infect
analyz
hcv
genoeyp
threeyearfollowup
studi
cmdren
leukemia
lymphoma
undergo
chemotherapi
method
studi
group
consist
children
without
hcv
antibodi
hcvab
time
diagnosi
hcvab
estim
eia
test
iind
gener
organon
tekmka
presenc
hcvrna
partid
genotyp
detect
nest
pcr
method
line
probe
assay
innolipa
hcv
result
appear
hcvab
therapi
observ
patient
median
time
month
dmgnosi
among
children
posit
hcvab
patient
rnahcv
confirm
pcr
result
everi
examin
hcvfwa
posit
case
infect
hcv
slngle
genotyp
includmg
type
la
chddren
type
l
b
patient
coinfect
two
genotyp
hcv
observ
two
patient
lalb
none
hcvrna
posit
childsen
becam
neg
studi
conclus
persist
viremia
hcvmfect
patient
explain
therapyinduc
immunosuppress
hcv
genotyp
almost
analyz
children
strongli
suggest
common
sourc
hcv
lnfection
infect
children
serious
consid
chemotherapi
work
sponsor
kbn
grant
cytomegaloviru
cmv
lnfection
remain
frequent
mfection
allogen
bone
marrow
transplant
abmt
demonstr
cmv
clinic
sampl
princip
approach
diagnosi
cmv
infect
object
determin
whether
use
prolong
antivir
prophylaxi
affect
detect
cmv
shell
vial
assay
sva
convent
cell
cultur
cc
surveil
specimen
abmt
method
total
patient
abmt
cmv
sero
andor
donor
sero
prospect
monitor
week
detect
cmv
blood
urin
throat
bronchoalveolar
lavag
bal
sva
cc
cell
line
receiv
high
dose
acyclovlr
hd
acv
h
day
bmt
group
receiv
hd
acv
day
dadclovir
h
acv
oral
h
week
post
bmt
group
b
patient
enrol
prospect
trlal
compar
antivir
prophyh
major
problem
renal
allohansplant
reject
crise
infecti
complic
requir
rather
e
r
e
n
therapeut
behaviour
infect
could
variou
origin
howev
wal
etiolog
bigger
problem
transplantologist
nephrologist
immunologist
cours
patient
author
present
studi
examin
dynarmc
recipi
renal
allograft
use
method
immunolog
monitor
also
microbiolog
virolog
biolog
test
well
inhenc
immunomodul
antivir
therapi
altogeth
infecti
complic
regist
first
month
transplant
patient
infect
viral
origin
etiolog
follow
hepat
u
e
n
z
cmv
adenovd
echo
herp
hiv
seroposit
viruscarri
worthment
longterm
studi
cover
period
recent
year
patient
hiv
etiolog
viral
mfectiou
complic
regist
first
period
investig
time
aidstest
consid
obligatori
examin
haemodialysi
center
immunoreact
type
patient
viral
mfection
renal
allotransplant
show
lower
activ
whlch
could
explain
easytodevelop
lnfectiou
process
h
one
hand
fiom
hand
obviou
recipi
show
consider
less
number
reject
episod
compar
patient
preliminari
higher
immunoreact
statu
model
immunolog
monitor
allow
reliabl
predict
differenti
magnosi
reject
infect
renal
allotransplant
f
reusser
r
attenhof
g
cathoma
tamm
g
thiel
univers
hospit
basel
switzerland
cmvspecif
hla
class
irestrict
ctl
thought
play
import
role
control
cmv
mfection
diseas
pcrbase
detect
cmv
dna
blood
specimen
permit
recognit
cmv
infect
earli
stage
studi
patient
pa
first
month
rtx
cmvseroposit
rtx
pt
seroneg
seroposit
kidney
donor
pt
cmvspecif
ctl
respons
peripher
blood
assess
month
rtx
blood
mononuclear
cell
cocultur
cmvinfect
autolog
fibroblast
week
test
c
releas
assay
cytotox
cmvinfect
e
c
e
autolog
hlamismatch
fibroblast
pcr
use
detect
cmv
dna
blood
leukocyt
week
assay
consid
posit
consecut
blood
specimen
pcrposit
first
month
rtx
cmvspecif
ctl
activ
demonstr
pt
cmv
dna
detect
blood
pt
median
rang
day
associ
presenc
cmvspecif
ctl
cmv
dna
blood
month
first
ctl
detect
p
cmv
ctseas
develop
pt
invers
correl
presenc
specif
ctl
respons
cmv
eas
rtx
p
conclus
cmvspecif
ctl
appear
suppress
cmv
lnfection
detect
pcr
peripher
blood
first
month
rtx
contrast
cmvspecif
ctl
respons
mediat
protect
h
cmv
diseas
period
rtx
method
initi
ebv
statu
donor
recipi
adult
heart
transplant
determin
teshng
ebv
viral
